Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|June 1, 2014

BioPharm International

  • BioPharm International-06-01-2014
  • Volume 27
  • Issue 6

Handheld Analyzer Improves Accuracy

Author(s)Melanie Sena

Handheld Analyzer Improves Accuracy

Rigaku Raman Technologies’ handheld ramen analyzer, the Rigaku Progeny, is designed to deliver accurate materials identification and improve ease of use, adaptability, and reliability. The Progeny has a 1064 nm high-power excitation laser, which increases speed and sensitivity of analysis and minimizes fluorescence interferences. A 512-pixel detector delivers improved resolution, analytics, and signal-to-noise ratio for handling challenging mixture analyses. The sealed system (IP-68) guards against moisture and dust, enabling rugged warehouse use and easy cleaning while minimizing cross-contamination risk.

The ergonomic design and shape provide single-hand entry into industrial barrels/drums, allowing users to view the screen while the instrument is in a downward orientation. The Progeny’s customizable workflow software is 21 CFR Part 11 compliant and has a smart phone-inspired user interface allowing quick implementation of material ID methods.

Rigaku Raman Technologies

Articles in this issue

over 12 years ago

TOC Analyzer Increases Productivity

over 12 years ago

A Sampling of New Tools for Downstream Processing

over 12 years ago

Finished Product Monographs in the European Pharmacopoeia

over 12 years ago

Global Expansion Shapes Drug Oversight

over 12 years ago

Bureaucratic Roadblocks Threaten Biopharma Growth

over 12 years ago

Outsourcing No Longer Just for Cost-Cutting

over 12 years ago

Challenges in Analytical Method Development and Validation

over 12 years ago

Brunei's Potential Pharmaceutical Market Growth

over 12 years ago

Assuring Equivalency of Alternative Lot-Release Test Methods

over 12 years ago

Concentrating Feed—an Applicable Approach to Improve Antibody Production

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more